TY  - JOUR
A1  - Henderson, Colin J.
A1  - Scheer, Nico
A1  - Wolf, C. Roland
T1  - Advances in the generation of mouse models to elucidate the pathways of drug metabolism in rodents and man
JF  - Expert Review of Clinical Pharmacology
Y1  - 2009
U6  - http://dx.doi.org/10.1586/17512433.2.2.105
SN  - 1751-2441
VL  - 2
IS  - 2
SP  - 105
EP  - 109
PB  - Taylor & Francis
CY  - London
ER  - 
TY  - JOUR
A1  - Stanley, Lesley A.
A1  - Horsburgh, Brian C.
A1  - Ross, Jillian
A1  - Scheer, Nico
A1  - Wolf, C. Roland
T1  - Drug transporters: Gatekeepers controlling access of xenobiotics to the cellular interior
JF  - Drug Metabolism Reviews
Y1  - 2009
U6  - http://dx.doi.org/10.1080/03602530802605040
SN  - 1097-9883
VL  - 41
IS  - 1
SP  - 27
EP  - 65
PB  - Taylor & Francis
CY  - London
ER  - 
TY  - JOUR
A1  - Stanley, Lesley A.
A1  - Horsburgh, Brian C.
A1  - Ross, Jillian
A1  - Scheer, Nico
A1  - Wolf, C. Roland
T1  - Nuclear Receptors which play a pivotal role in drug disposition and chemical toxicity
JF  - Drug Metabolism Reviews
Y1  - 2006
U6  - http://dx.doi.org/10.1080/03602530600786232
SN  - 1097-9883
VL  - 38
IS  - 3
SP  - 515
EP  - 597
ER  - 
TY  - CHAP
A1  - Samuelsson, K.
A1  - Scheer, Nico
A1  - Wilson, I.
A1  - Wolf, C.R.
A1  - Henderson, C.J.
ED  - Chackalamannil, Samuel
T1  - Genetically Humanized Animal Models
T2  - Comprehensive Medicinal Chemistry III. 3rd Edition
N2  - Genetically humanized mice for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging as promising in vivo models for improved prediction of the pharmacokinetic, drug–drug interaction, and safety characteristics of compounds in humans. This is an overview on the genetically humanized and chimeric liver-humanized mouse models, which are illustrated with examples of their utility in drug metabolism and toxicity studies. The models are compared to give guidance for selection of the most appropriate model by highlighting advantages and disadvantages to be carefully considered when used for studies in drug discovery and development.
KW  - Chimeric liver-humanized mice
KW  - Drug distribution
KW  - Drug metabolism
KW  - Toxicology
KW  - Knockout mice
Y1  - 2017
SN  - 978-0-12-803201-5
U6  - http://dx.doi.org/10.1016/B978-0-12-409547-2.12376-5
SP  - 130
EP  - 149
PB  - Elsevier
CY  - Saint Louis
ER  - 
TY  - CHAP
A1  - Scheer, Nico
A1  - Chu, Xiaoyan
A1  - Salphati, Laurent
A1  - Zamek-Gliszczynski, Maciej J.
ED  - Nicholls, Glynis
T1  - Knockout and humanized animal models to study membrane transporters in drug development
T2  - Drug Transporters: Volume 1: Role and Importance in ADME and Drug Development
Y1  - 2016
SN  - 978-1-78262-379-3
U6  - http://dx.doi.org/10.1039/9781782623793-00298
SP  - 298
EP  - 332
PB  - Royal Society of Chemistry
CY  - Cambridge
ER  - 
TY  - CHAP
A1  - Wolf, C. Roland
A1  - Kapelyukh, Yury
A1  - Scheer, Nico
A1  - Henderson, Colin J.
ED  - Wilson, Alan G. E.
T1  - Application of Humanised and Other Transgenic Models to Predict Human Responses to Drugs
N2  - The use of transgenic animal models has transformed our knowledge of complex biochemical pathways in vivo. It has allowed disease processes to be modelled and used in the development of new disease prevention and treatment strategies. They can also be used to define cell- and tissue-specific pathways of gene regulation. A further major application is in the area of preclinical development where such models can be used to define pathways of chemical toxicity, and the pathways that regulate drug disposition. One major application of this approach is the humanisation of mice for the proteins that control drug metabolism and disposition. Such models can have numerous applications in the development of drugs and in their more sophisticated use in the clinic.
Y1  - 2015
SN  - 978-1-78262-778-4
U6  - http://dx.doi.org/10.1039/9781782622376-00152
SP  - 152
EP  - 176
PB  - RSC Publ.
CY  - Cambridge
ER  - 
TY  - CHAP
A1  - Henderson, Colin J.
A1  - Wolf, C. Roland
A1  - Scheer, Nico
ED  - Woolf, Thomas F.
T1  - The use of transgenic animals to study drug metabolism
T2  - Handbook of Drug Metabolism. 2nd Edition
Y1  - 2009
SN  - 978-1-4200-7647-9
SP  - 637
EP  - 658
PB  - Informa Healthcare
CY  - New York
ER  - 
TY  - JOUR
A1  - Engel, Mareike
A1  - Bayer, Hendrik
A1  - Holtmann, Dirk
A1  - Tippkötter, Nils
A1  - Ulber, Roland
T1  - Flavin secretion of Clostridium acetobutylicum in a bioelectrochemical system - Is an iron limitation involved?
JF  - Bioelectrochemistry
Y1  - 2019
U6  - http://dx.doi.org/10.1016/j.bioelechem.2019.05.014
SN  - 1567-5394
IS  - In Press, Accepted Manuscript
PB  - Elsevier
CY  - Amsterdam
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Ross, Jillian
A1  - Rode, Anja
A1  - Zevnik, Branko
A1  - Niehaves, Sandra
A1  - Faust, Nicole
A1  - Wolf, C. Roland
T1  - A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response
JF  - Journal of Clinical Investigation
Y1  - 2008
U6  - http://dx.doi.org/https://doi.org/10.1172/JCI35483
SN  - 1558-8238
VL  - 118
IS  - 9
SP  - 3228
EP  - 3239
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Kapelyukh, Yury
A1  - McEwan, Jillian
A1  - Beuger, Vincent
A1  - Stanley, Lesley A.
A1  - Rode, Anja
A1  - Wolf, C. Roland
T1  - Modeling Human Cytochrome P450 2D6 Metabolism and Drug-drug Interaction by a Novel Panel of Knockout and Humanized Mouse Lines
JF  - Molecular Pharmacology
N2  - The highly polymorphic human cytochrome P450 2D6 enzyme is involved in the metabolism of up to 25% of all marketed drugs and accounts for significant individual differences in response to CYP2D6 substrates. Because of the differences in the multiplicity and substrate specificity of CYP2D family members among species, it is difficult to predict pathways of human CYP2D6-dependent drug metabolism on the basis of animal studies. To create animal models that reflect the human situation more closely and that allow an in vivo assessment of the consequences of differential CYP2D6 drug metabolism, we have developed a novel straightforward approach to delete the entire murine Cyp2d gene cluster and replace it with allelic variants of human CYP2D6. By using this approach, we have generated mouse lines expressing the two frequent human protein isoforms CYP2D6.1 and CYP2D6.2 and an as yet undescribed variant of this enzyme, as well as a Cyp2d cluster knockout mouse. We demonstrate that the various transgenic mouse lines cover a wide spectrum of different human CYP2D6 metabolizer phenotypes. The novel humanization strategy described here provides a robust approach for the expression of different CYP2D6 allelic variants in transgenic mice and thus can help to evaluate potential CYP2D6-dependent interindividual differences in drug response in the context of personalized medicine.
Y1  - 2012
U6  - http://dx.doi.org/10.1124/mol.111.075192
SN  - 1521-0111
VL  - 81
IS  - 1
SP  - 63
EP  - 72
PB  - ASPET
CY  - Bethesda, Md.
ER  - 
TY  - JOUR
A1  - Reugels, Alexander M.
A1  - Boggetti, Barbara
A1  - Scheer, Nico
A1  - Campos-Ortega, José A.
T1  - Asymmetric localization of Numb:EGFP in dividing neuroepithelial cells during neurulation in Danio rerio
JF  - Developmental Dynamics
Y1  - 2006
U6  - http://dx.doi.org/10.1002/dvdy.20699
SN  - 1097-0177
VL  - 235
IS  - 4
SP  - 934
EP  - 948
ER  - 
TY  - JOUR
A1  - Hans, Stefan
A1  - Scheer, Nico
A1  - Riedl, Iris
A1  - Weizäcker, Elisabeth von
A1  - Blader, Patrick
A1  - Campos-Ortega, José A.
T1  - her3, a zebrafish member of the hairy-E(spl) family, is repressed by Notch signalling
JF  - Development
Y1  - 2004
U6  - http://dx.doi.org/10.1242/dev.01167
SN  - 1477-9129
VL  - 131
IS  - 12
SP  - 2957
EP  - 2969
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Riedl, Iris
A1  - Warren, J.T.
A1  - Kuwada, John Y.
A1  - Campos-Ortega, José A.
T1  - A quantitative analysis of the kinetics of Gal4 activator and effector gene expression in the zebrafish
JF  - Mechanism of Development
Y1  - 2002
U6  - http://dx.doi.org/10.1016/S0925-4773(01)00621-9
SN  - 0925-4773
VL  - 112
IS  - 1-2
SP  - 9
EP  - 14
ER  - 
TY  - JOUR
A1  - Lawson, Nathan D.
A1  - Scheer, Nico
A1  - Pham, Van N.
A1  - Kim, Ceol-Hee
A1  - Chitnis, Ajay B.
A1  - Campos-Ortega, José A.
A1  - Weinstein, Brant M.
T1  - Notch signaling is required for arterial-venous differentiation during embryonic vascular development
JF  - Development
Y1  - 2001
SN  - 1477-9129
VL  - 128
IS  - 19
SP  - 3675
EP  - 3683
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Groth, Anne
A1  - Hans, Stefan
A1  - Campos-Ortega, José A.
T1  - An instructive function for Notch in promoting gliogenesis in the zebrafish retina
JF  - Development
Y1  - 2001
SN  - 0950-1991
VL  - 128
IS  - 7
SP  - 1099
EP  - 1107
ER  - 
TY  - JOUR
A1  - Halbach, Thorsten
A1  - Scheer, Nico
T1  - Transcriptional activation by the PHD finger is inhibited through an adjacent leucine zipper that binds 14-3-3 proteins
JF  - Nucleic Acids Research
Y1  - 2000
U6  - http://dx.doi.org/10.1093/nar/28.18.3542
SN  - 1362-4962
VL  - 28
IS  - 18
SP  - 3542
EP  - 3550
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Campos-Ortega, José A.
T1  - Use of the Gal4-UAS technique for targeted gene expression in the zebrafish
JF  - Mechanism of Development
Y1  - 1999
U6  - http://dx.doi.org/10.1016/S0925-4773(98)00209-3
SN  - 0925-4773
VL  - 80
IS  - 2
SP  - 153
EP  - 158
ER  - 
TY  - PAT
A1  - Friederici, Nadja-Annette
A1  - Hojdis, Nils
T1  - Fahrzeugreifen
N2  - Die Erfindung betrifft einen Fahrzeugreifen mit zumindest einem radial außen befindlichen Gummilaufstreifen, Wulstbereichen für den Anschluss an eine Felge und mit auf einer Gummimischung basierenden Seitenwandbereichen zwischen Gummilaufstreifen und den Wulstbereichen. Ferner betrifft die Erfindung Verfahren zur Herstellung solcher Fahrzeugreifen. Um den Anteil der umweltschädlichen Substanzen, insbesondere im Innenstadtbereich, zu reduzieren weisen die Seitenwandbereiche auf der äußeren Oberfläche eine für den oxidativen Abbau von Molekülen photokatalytisch aktive Substanz auf.
Y1  - 2018
N1  - Patent DE102016219338A1 04.12.2018
ER  - 
TY  - PAT
A1  - Hojdis, Nils
A1  - Multhaupt, Hendrik
A1  - Recker, Carla
A1  - Wark, Michael
T1  - Schwefelvernetzbare Kautschukmischung, Vulkanisat der Kautschukmischung und Fahrzeugreifen
N2  - Die Erfindung betrifft eine schwefelvernetzbare Kautschukmischung, deren Vulkanisat und einen Fahrzeugreifen. Die erfindungsgemäße Kautschukmischung enthält wenigstens folgende Bestandteile: - Wenigstens einen Dienkautschuk; - wenigstens eine Kohle (HTC-Kohle), die mittels hydrothermaler Karbonisierung von wenigstens einer Ausgangssubstanz hergestellt ist. Der erfindungsgemäße Fahrzeugreifen weist in wenigstens einem Bauteil wenigstens ein erfindungsgemäßes Vulkanisat der Kautschukmischung auf.
Y1  - 2019
N1  - Patent EP3470457A1 17.04.2019
auch veröffentlicht unter WO2019072431A1
ER  - 
TY  - PAT
A1  - Dauer, David-Raphael
A1  - Hojdis, Nils
A1  - Müller, Norbert
A1  - Recker, Carla
A1  - Schax, Fabian
A1  - Schöffel, Julia
A1  - Tarantola, Gesa
A1  - Weber, Christine
T1  - Schwefelvernetzbare Kautschukmischung, Vulkanisat der Kautschukmischung und Fahrzeugreifen
N2  - Die Erfindung betrifft eine schwefelvernetzbare Kautschukmischung, deren Vulkanisat und einen Fahrzeugreifen. Die schwefelvernetzbare Kautschukmischung enthält wenigstens die folgenden Bestandteile: - wenigstens einen Dienkautschuk; und - 10 bis 300 phr wenigstens einer Kieselsäure; und - 1 bis 30 phf wenigstens eines Silans A mit der allgemeinen Summenformel A-I) A-I)(R1)oSi-R2-(S-R3)q-S-X; und - 0,5 bis 30 phf wenigstens eines Silans B mit der allgemeinen Summenformel B-I) B-I) (R1)oSi-R2-(S-R3)u-S-R2-Si(R1)o wobei q =1, 2 oder 3 ist; und u = 1, 2 oder 3 ist; und X ein Wasserstoffatom oder eine –C(=O)-R8 Gruppe ist wobei R8 ausgewählt ist aus Wasserstoff, C1-C20 Alkylgruppen, vorzugsweise C1-C17, C6-C20- Arylgruppen, vorzugsweise Phenyl, C2-C20-Alkenylgruppen und C7-C20-Aralkylgruppen.
Y1  - 2019
N1  - Patent WO2019105614A1 06.06.2019
auch veröffentlicht unter 
CN111386199A; DE102017221232A1; 
 TW201925306A
ER  -